163 related articles for article (PubMed ID: 37037489)
1. Everolimus in combination with octreotide LAR in thymic atypical carcinoid.
Sakane T; Nakano T; Hagui E; Haneda H; Okuda K
Thorac Cancer; 2023 May; 14(15):1404-1407. PubMed ID: 37037489
[TBL] [Abstract][Full Text] [Related]
2. [Two cases of thymic carcinoid treated with octreotide long-acting repeatable].
Okabe N; Inoue T; Watanabe Y; Muto S; Hasegawa T; Ohsugi J; Higuchi M; Shio Y; Suzuki H
Gan To Kagaku Ryoho; 2014 Jul; 41(7):879-83. PubMed ID: 25131876
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
Ferolla P; Brizzi MP; Meyer T; Mansoor W; Mazieres J; Do Cao C; Léna H; Berruti A; Damiano V; Buikhuisen W; Grønbæk H; Lombard-Bohas C; Grohé C; Minotti V; Tiseo M; De Castro J; Reed N; Gislimberti G; Singh N; Stankovic M; Öberg K; Baudin E
Lancet Oncol; 2017 Dec; 18(12):1652-1664. PubMed ID: 29074099
[TBL] [Abstract][Full Text] [Related]
4. [A Case of Primary Thymic Carcinoid Treated with Everolimus and Octreotide].
Katagiri Y; Yanagawa N; Shiono S; Yuki Y; Muramatsu S; Hino T; Suzuki H
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1445-1447. PubMed ID: 31530787
[TBL] [Abstract][Full Text] [Related]
5. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
[TBL] [Abstract][Full Text] [Related]
6. Metastatic thymic carcinoid responds to chemoradiation and octreotide: A case report.
Mei Z; Wang H; Ren S; Wei J; Gu Y
Medicine (Baltimore); 2018 Nov; 97(47):e13286. PubMed ID: 30461637
[TBL] [Abstract][Full Text] [Related]
7. Incidental metastatic mediastinal atypical carcinoid in a patient with parathyroid adenoma: a case report.
Kiran Z; Ahmed A; Rashid O; Fatima S; Malik F; Fatimi S; Ikram M
J Med Case Rep; 2017 Mar; 11(1):81. PubMed ID: 28342443
[TBL] [Abstract][Full Text] [Related]
8. Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report.
Dham A; Truskinovsky AM; Dudek AZ
J Thorac Oncol; 2008 Jan; 3(1):94-7. PubMed ID: 18166847
[TBL] [Abstract][Full Text] [Related]
9. [A case of rectal carcinoid with multiple liver, lymph nodes and bone metastases that responded to an octreotide therapy].
Yamashita K; Takase S; Nakamura T; Matsuda Y; Imanishi T; Sumi Y; Suzuki S; Kamigaki T; Ku Y; Kuroda D
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2349-51. PubMed ID: 21224569
[TBL] [Abstract][Full Text] [Related]
10. [Thymic carcinoid with lymph node metastases; report of a case].
Nakamura Y; Sato N; Kaimori K; Imai T
Kyobu Geka; 2007 Dec; 60(13):1204-7. PubMed ID: 18078092
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
[TBL] [Abstract][Full Text] [Related]
12. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC
Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.
Yao JC; Phan AT; Chang DZ; Wolff RA; Hess K; Gupta S; Jacobs C; Mares JE; Landgraf AN; Rashid A; Meric-Bernstam F
J Clin Oncol; 2008 Sep; 26(26):4311-8. PubMed ID: 18779618
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.
Pavel ME; Baudin E; Öberg KE; Hainsworth JD; Voi M; Rouyrre N; Peeters M; Gross DJ; Yao JC
Ann Oncol; 2017 Jul; 28(7):1569-1575. PubMed ID: 28444114
[TBL] [Abstract][Full Text] [Related]
15. Lung and Thymic Carcinoids.
Hann CL; Forde PM
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):699-709. PubMed ID: 30098725
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
17. [Multimodal therapy improved carcinoid syndrome secondary to liver metastases of an atypical lung carcinoid tumor:a case report].
Shimizu T; Adikrisna R; Shimada K; Uchidate K; Fukuda K; Oyama A; Ueda M; Goto F; Suzuki M; Kawamura T
Nihon Shokakibyo Gakkai Zasshi; 2020; 117(7):635-645. PubMed ID: 32655123
[TBL] [Abstract][Full Text] [Related]
18. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
[TBL] [Abstract][Full Text] [Related]
19. Ectopic ACTH syndrome due to thymic atypical carcinoid treated with combination chemotherapy of cisplatin and etoposide.
Takahashi T; Hatao K; Yamashita Y; Tanizawa Y
Intern Med; 2003 Dec; 42(12):1197-201. PubMed ID: 14714958
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute.
Han B; Sun JM; Ahn JS; Park K; Ahn MJ
Med Oncol; 2013 Mar; 30(1):479. PubMed ID: 23377986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
